Target Name: CD7
NCBI ID: G924
Review Report on CD7 Target / Biomarker Content of Review Report on CD7 Target / Biomarker
CD7
Other Name(s): T-cell antigen CD7 precursor | CD7_HUMAN | T-cell antigen CD7 | GP40 | CD7 antigen (p41) | p41 protein | T-cell surface antigen Leu-9 | TP41 | CD7 molecule | LEU-9 | T-cell leukemia antigen | TP40 | Tp40

CD7: A promising drug target and biomarker for T-cell activation and regulation

CD7 is a cell surface antigen that is expressed in most T-cells, as well as some B-cells and natural killer cells. It is a type I transmembrane protein that is composed of a pre-伪 and a post-伪 portion. The post-伪 portion of CD7 contains a T-cell antigen that is involved in T-cell activation and regulation.

CD7 is involved in the development and activation of T-cells, as well as their ongoing regulation. It is a key regulator of T-cell receptor (TCR) activation, as well as the co-stimulation of T-cells with CD28. T-cell activation and regulation are critical for the immune response, and CD7 plays a crucial role in this process.

CD7 is also a potential drug target and biomarker for T-cell-related diseases. Several studies have suggested that targeting CD7 may be an effective way to treat T-cell-related disorders, including autoimmune diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS) (3,4).

CD7 function and interactions

CD7 is involved in the regulation of T-cell activation and co-stimulation. It is a co-stimulatory molecule for the T-cell receptor (TCR), which is a critical receptor for T-cell activation. CD7 can interact with the T-cell receptor through its extracellular domain, leading to increased T-cell activation and clonal expansion.

CD7 is also involved in the regulation of T-cell proliferation and differentiation. It can induce the expression of programs involved in T-cell proliferation, such as the PD-1/PD-L1 pathway, which is critical for T-cell survival and function. Additionally, CD7 can regulate the exit of T-cells from the body, which is important for their ongoing function and for immune surveillance.

CD7 is also involved in the regulation of immune cell function, including the regulation of inflammation and immune tolerance. It can modulate the production of immune cells, such as natural killer cells and T-cells, and can also play a role in the regulation of inflammation.

CD7 dysfunction and diseases

CD7 dysfunction has been implicated in several T-cell-related diseases, including RA, MS, and other autoimmune disorders (10,11). Several studies have suggested that targeting CD7 may be an effective way to treat these diseases. For example, clinical trials have shown that targeting CD7 with drugs such as CTLA-4 and PD-1 have been effective in treating RA and MS (12,13).

In addition to its role in T-cell activation and regulation, CD7 has also been suggested as a potential biomarker for these diseases. Several studies have shown that changes in CD7 expression can be detected in individuals with RA and MS, and these changes can be associated with the severity of disease (14,15).

CD7 targeting and therapy

Several studies have suggested that targeting CD7 may be an effective way to treat T-cell-related diseases, including RA and MS. CD7 has been targeted with drugs such as CTLA-4 and PD-1, which are designed to inhibit the activity of CD7 and its downstream signaling pathways (16,17). These drugs have been shown to be effective in treating RA and MS, with some studies reporting significant improvements in symptoms and radiological scores (18,19).

In addition to targeting CD

Protein Name: CD7 Molecule

Functions: Not yet known

The "CD7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2